References
- MacKenzie M. R., Fudenberg H. H. Macroglobulinemia-an analysis of forty patients. Blood 1972; 39: 874–889
- Petrucci M. T., Avvisati G., Tribalto M., Giovangrossi P., Mandelli F. Waldenstrom's macroglobulin-emia—results in 34 newly diagnosed patients. J. Intern. Med. 1989; 26: 443–447
- Case D. C., Ervin T. J., Boyd M. A., Redfield D. L. Waldenstrom's macroglobulinemia: Long term results with the M-2 protocol. Cancer Invest. 1991; 9: 1–7
- Kantarjian H. M., Alexanian R., Koller C. A., Kurzrock R., Keating M. 3. Fludarabine therapy in ma-croglobulinemic lymphoma. Blood 1990; 75: 1928–1931
- Dimopoulos M. A., Kantarjian H., Estey E., O'Brien S., Delasalle K., Keating M. J., Freireich E. J., Alexanian R. Treatment of Waldenstrom's macroglobulinemia with 2–chlorodeoxyadenosine. Ann. Intern. Med. 1993; 118: 195–198
- McLaughlin P., Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 1982; 60: 851–854
- Claman G. H., Corder M. P., Bums C. P. Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents. Am. J. Hematol. 1980; 9: 221–223
- Jane S. M., Salem H. H. Treatment of resistant Waldenstrom's macroglobulinemia with high dose glucoco-steroids. Aust. N.Z. J. Med. 1988; 18: 77–78
- Ohno R., Kodera Y., Ogura M., Murase T., Emi N., Okumura M., Kobayashi M., Takeyama H. Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. Cancer Chemother. Pharmacol. 1985; 14: 34–37
- Quesada J. R., Alexanian R., Kurzrock R., Barlogie B., Saks S., Gutterman J. U. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma and Waldenstrom's macroglobulinemia. Am. J. Hematol. 1988; 29: 1–4
- Bruera E., Villamayor R., Roca E., Barugel M., Trouce J., Chacon R. Response of Waldenstrom's macroglobulinemia to pentostatin. Cancer Treat. Rep. 1986; 70: 546–547
- Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2–chlorodeoxyadenosine. N. Engl. J. Med. 1990; 322: 1117–1121
- Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2–chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
- Keating M. J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–26
- Hochster H. S., Kim L., Green M. D., Mann R. B., Nei-Man R. S., Oken M. M., Cassileth P. A., Stott P., Ritch P., O'Connell M. J. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma. J. Clin. Oncol. 1992; 10: 28–32
- Redman J. R., Cabanillas F., Velasquez W. S., Mc-Langhlin P., Hagemeister F. B., Swan F., Rodriguez M. A., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma. J. Clin. Oncol. 1992; 10: 790–794
- Kay A. C., Saven A., Carrera C. J., Carson D. A., Thur-Ston D., Beutler E., Piro L. D. 2–chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
- Huang P., Chubb S., Plunkett W. Incorporation of 9–b-d-Arabinofuranosy 1–2–fluoroadenine DNA and its chain termination effect on DNA synthesis. J. Biol. Chem. 1990; 265: 1617–1625
- Beutler E., Piro L. D., Saven A., Kay A. C., McMillan R., Longuire R., Carson D. A. 2–chlorodeoxyadenosine: A potent chemotherapeutic and immunosuppres-sive nucleoside. Leukemia and Lymphoma 1991; 5: 1–8
- Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2–chloro-d'deoxyadenosine and 9–b-d-Arabinosyl-2–fluoroad-enine. Blood 1993; 81: 143–150
- Kawasaki H., Carrera C. J., Piro L. D., Saven A., Kipps T. I., Carson D. A. Relationship of deoxycytine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2–chlorodeoxyadenosine. Blood 1993; 81: 597–601